A fixed-dose combination of Sitagliptin (a DPP-4 inhibitor) and Metformin (a biguanide) used for the management of type 2 diabetes mellitus. Sitagliptin enhances incretin activity to increase insulin secretion and suppress glucagon, while Metformin decreases hepatic glucose production and improves insulin sensitivity.
Reviews
There are no reviews yet.